ArticleNaunyn-Schmiedeberg's archives of pharmacology2025
Taurine alleviates colitis by regulating oxidative stress, inflammatory responses, ER stress, and apoptotic pathways.
Article in Naunyn-Schmiedeberg's archives of pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- A 4-guanidinobutanoic acid-SLC36A1 axis drives a microbiota‒host feedback loop to regulate intestinal homeostasis.Gut microbes · 2026Article
- Gene Expression Alterations in Peripheral Blood Mononuclear Cells and Cartilage Explants from End-Stage Rheumatoid Arthritis Patients in Response to Taurine: A Pilot Exploratory Study.Life (Basel, Switzerland) · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colitis is an inflammatory condition affecting the colon, characterized by oxidative stress, ER stress, and apoptosis, which leads to severe tissue damage. Existing treatments are associated with significant side effects, necessitating the exploration of alternative therapeutic agents. Taurine is a commonly consumed bioactive sulfur-containing amino acid, recognized for its cyto-protective property. In this study, we are using a male Wistar rat model for 2,4,6-trinitrobenzenesulfonic acid (TNBS)-induced colitis and treated them with taurine. Colitis development was indicated by repeated loose bloody stools, reduced appetite, and weight loss. Macroscopic examination revealed an inflamed colon surface with ulcerations, while histopathology showed a destroyed crypt structure and damage to the epithelial and mucosal layers in the colitis-affected rats. However, taurine administration reverses such adverse effects of colitis. Taurine significantly mitigates the oxidative stress by upregulating the level of anti-oxidant molecules, such as CAT, GST and SOD, which were significantly down-regulated in colitis. In addition, increased levels of inflammatory molecules (TNF-α, IL- 1β, IL- 6, MCP- 1, ICAM- 1, and VCAM- 1) in colitis were reduced by taurine supplementation. Furthermore, we observed taurine alleviates colitis induced up-regulation of important endoplasmic reticulum (ER) stress markers like, CHOP, GRP78, calpain 1, and caspase 12. We have also demonstrated that taurine supplementation reverses colitis induced apoptosis by assessing the modulation of apoptotic markers (Bax, Bcl- 2, caspase 9 and caspase 3). Furthermore, no instances of toxicity from taurine were observed. Thus, taurine shows a potential to be utilized as a therapeutic agent for colitis with further detailed investigation.
Indexed as
Identifiers
40227309What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.